We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Prevalence of hypertension by BMI and AGE
- Abdominal obesity and blood presure
- Obesity and MI: case control study
- BMI categories with MI risk: waist-to-hip ratio
- Obesity and cardiovascular risk
- Vital statistic: waist circumference
- Pathophysiology of obesity hypertension
- Hemodynamic alterations in obese adolescents
- High fat diet causes Na retention and hypertension
- Leptin acts as a lipostat
- Carotid artery leptin infusion decreases food intake
- Leptin infusion increases arterial pressure
- Leptin in obese normotensives and hypertensives
- Leptin and sympathetic nerve activity
- Cardiorenal effects of obesity
- Renin-angiotensin system in obesity
- Renin-angiotensin genes expression in adipocytes
- AT1 receptor expression on human adipocytes
- Meta-Analysis of RCTs
- Antihypertensive agents in obese hypertensives
- Treatment of obesity hypertension
- Trial of hypertension prevention of weight-loss arm
- Currently approved antiobesity agents
- Orlistat promotes clinically significant weight loss
- Orlistat: effect on blood pressure in hypertensives
- Study: sibutramine in obese hypertensive patients
- Reality: CV side effects in sibutramine trials
- BP changes in sibutramine-treated patients
- Sympathetic stimulation: handgrip test
- Sympathetic stimulation: cold pressor test
- Plasma noradrenaline: supine
- Sibutramine affects sympathetic activity
- Sibutramine: Scout study
- Bariatric surgery: effect on cardiovascular risk
- Summary and Conclusions
Topics Covered
- Prevalence of hypertension
- Abdominal obesity and blood pressure
- Myocardial infarction risk
- Obesity and cardiovascular risk
- Pathophysiology of obesity hypertension
- Leptin
- Cardiorenal effects of obesity
- Renin-angiotensin system in obesity
- Treatment of obesity hypertension
- Currently approved anti-obesity agents: Orlistat and Sibutramine
- Bariatric surgery
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Sharma, A. (2007, October 1). Pathophysiology and management of obesity related hypertension [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2024, from https://doi.org/10.69645/XAQU8193.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Arya Sharma has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Pathophysiology and management of obesity related hypertension
Published on October 1, 2007
23 min